Oxybis(methyl-2,1-ethanediyl) diacrylate

Endpoint summary

Description of key information

Oral
Rat:
- LD50 = 3530 mg/kg bw (BASF AG 1987, Val. 2)
- LD50 = 4626 mg/kg bw (WIL Res Labs Inc. 1982, Val. 2)
 
Inhalation
Rat, IHT: 7 h: LC0 = 0.545 mg/m3 air (BASF AG 1982, Val. 2); Read across to CAS No. 42978-66-5
Dermal
Rabbit: LD50 > 2000 mg/kg bw (WIL Res Labs Inc. 1982, Val. 2)

Additional information

There are valid data available for the assessment of the acute oral and acute dermal toxicity of DPGDA.

 

Oral

In a standard acute test, comparable to OECD guideline 401, five male and five female Wistar rats were treated with 825, 1470, 2150, 3830 and 5000 mg/kg bw Laromer DPGDA under standardized conditions (BASF AG, 1987). The animals were observed for 14 d, necropsy was performed even with the survivors. The LD50 for males and females is 3530 mg/kg bw, for male rats the LD50 is 4270 mg/kg bw for and female rats the LD50 is 2810 mg/kg bw. No mortalities were seen at 825 mg/kg bw; 0/5 males and 1/5 females died at the 1470 mg/kg dose level; 1/5 males and 0/5 females died at the 2150 mg/kg dose level; 2/5 males and all females died at the 3830 mg/kg dose level; 3/5 males and 4/5 females died at the 5000 mg/kg dose level. No clinical symptoms of toxicity were observed at the 825 mg/kg bw dose level for either males or females; males of the 1470 mg/kg dose level exhibited dyspnea, apathy, staggering, piloerection and a poor general state on day 7; females of the 1470 mg/kg dose level exhibited dyspnea, apathy, staggering, piloerection and a poor general state from day 5 to day 7. Males of the 2150 mg/kg dose level exhibited dyspnea (day 2 to day 6), apathy (day 2 to day 6), staggering (day 6), piloerection (day 6), cyanosis (day 6) and a poor general state (day 2 to day 6); females of the 2150 mg/kg dose level exhibited dyspnea, apathy, staggering and a poor general state from day 2 to day 3. Males of the 3830 mg/kg dose level exhibited dyspnea, apathy, staggering, piloerection, a poor general state from day 1 to day 3, in addition diarrhea was observed during the first 4 hours after application; females of the 3830 mg/kg dose level exhibited dyspnea, apathy, staggering and a poor general state on day 1, in addition diarrhea was observed during the first 4 hours after application. Males of the 5000 mg/kg dose level exhibited dyspnea, apathy, staggering, and a poor general state from day 1 to day 3; females of the 5000 mg/kg dose level exhibited dyspnea, apathy, staggering, piloerection and a poor general state from day 1 to day 3, in addition spastic gait was observed from day 2 to day 3. No pathological findings were noted in animals of the 825 mg/kg bw dose group. From the animals that died (males and females) a general congestion was seen at the mucosa of glandular stomach was reddened. Two animals which died 6/7 days after administration of substance (1470, 2150 mg/kg bw) had intraabdominal adhesions. In addition one of them had hemorrhagic peritonitis. At doses of 1470 to 5000 mg/kg bw, intraabdominal adhesions and mucosa of forestomach with widespread hyperplasia was seen in the sacrificed animals (males and females).

In another acute oral toxicity test, also comparable to OECD 401, male and female rats were administered 1500, 3000, 5000 and 7500 mg/kg bw of the test material (WIL Res Labs Inc. 1982). Also here, the animals were observed for 14 d, and necropsy was performed even with the survivors. The LD50 for males and females was reported to be 4626 mg/kg bw. No deaths occured at 1500 mg/kg bw; at 3000 mg/kg bw 0/5 males and 1/5 females died; at 5000 mg/kg bw 2/5 males and 3/5 females died; at 7500 mg/kg bw all males and females died. Clinical signs of toxicity were reported: mild lethargy and ataxia, moderately loose or mucoid feces, urine and fecal stains (1500 and 3000 mg/kg dose levels) to slight to severe lethargy, ataxia, inactivity, moderately loose or mucoid feces, urine and fecal stains, red or yellow material around mouth, salivation, prostration with labored respiration, bodies cool to touch and death (5000 and 7500 mg/kg does levels). Positive gross pathologic findings were present and consisted of forestomach thickened and/or white, congested vessels over external surface of stomach, intestines pale (1500 mg/kg dose level), hindstomach markedly reddened, hemorrhage of forestomach, intestines reddened and vessels congested (found dead animals at 3000, 5000 and 7500 mg/kg dose levels), forestomach adhered to abdominal wall or rib cage (3000 mg/kg and 5000 mg/kg dose level, two survivors at each level) hindstomach pale (5000 mg/kg dose level, three survivors), liver red-black in color with/without pale areas along lobes (7500 mg/kg dose level, found dead animals).

 

Inhalation

There are no valid data available to assess the acute inhalative toxicity of DPGDA.

However, there are valid data available which assessed the inhalative toxicity of the structurally related substances tripropylene glycol diacrylate (Cas No. 42978-66-5)

In a standardized inhalation hazard test which was conducted with the structurally similar tripropylene glycol diacrylate (CAS No. 42978-66-5)

with a saturated vapour atmosphere, 0/12 Sprague-Dawley rats died after 7 h exposure (BASF AG 1982, Val. 2). The LC0 is 0.000545 mg/l air for male and female rats. Snout-wiping was the only sign of toxicity which was reported; the gross necropsy of all animals was inconspicuous.

 

Dermal

In an acute dermal toxicity test, comparable to OECD 402, 5 male and 5 female New Zealand White rabbits were administered 2000 mg/kg bw of the test material under occlusive conditions (WIL Res Labs Inc. 1982). The animals were observed for 14 days and necropsy was performed even with the survivors. The LD50 for males and females was reported to be >2000 mg/kg bw. No deaths occurred and signs of systemic toxicity were observed on day 1 gradually decreasing in severity and incidence to day 6, when they were no longer present. These signs consisted of the following: eyes appear bluish, ears cool to touch, increased rate of respiration, hunched backs, sporadic hyperactivity and decreased feces. The animals were in apparent severe pain and this, as well as the dosing procedure, would have been enough to produce these signs in the rabbits as they are easily stressed. A slight decrease in mean and individual body weights was present on day 6. By day 13 there was a slight increase in mean scores but several animals still had a weight loss. At gross necropsy the lungs were spotted dark red in color in 1/5 female animals, also in 4/5 males lungs dark red in color were seen. No significant other pathological findings were observed.

 

Read across justification:

 

DPGDA (CAS#57472-68-1) and TPGDA (CAS # 42978-66-5) are suitable for read across among each other as they are all structurally similar Difunctional Acrylates with comparable toxicological properties (all are sensitizing and have irritating effects on skin and eyes).

Justification for classification or non-classification

The available data for DPGDA indicate a relative low potential for acute toxicity.

 

In two reliable studies, the oral LD50 is 3530 mg/kg bw and LD50 = 4626 mg/kg bw, respectively for male and female rats. Therefore, DPGDA has not to be classified according to EU criteria (67/548/EEC or 1272/2008/EC). According to GHS-UN criteria it has to be classified as category 5 regarding this endpoint.

 

Since in inhalation hazard tests with rats exposed to saturated vapour atmospheres of the structurally similar test materials for 7 h revealed no mortality and only transient clinical signs, there is no indication given to classify the substance according to EU or GHS requirements for its acute inhalative toxicity as vapour.

 

In a reliable acute dermal study, the LD50 is >2000 mg/kg bw for male and female rabbits and no deaths occured. Therefore DPGDA has not to be classified regarding this endpoint.